Bibliografía del artículo
1. Jeppesen J, Hein HO, Suadicani P, Gynterberg F. Low triglycerides high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Int Med 2001;161:361-366.
2. Reaven MR. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
3. Lima NKC, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 2009;22:106-111.
4. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and euglycemic clamp. Diabetes 1981;30:387-392.
5. Blair D, Habicht JP, Sims EA, Sylwester D, Abraham S. Evidence for increased risk for hypertension with centrally located body fat and the effect of race and sex on the risk. Am J Epidemiol 1984;119:526-540.
6. Steiberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610.
7. Katchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens, advance online publication 12 August 2010.
8. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93:S57-S63.
9. Penesova A, Cizmarova E, Belan V e cols. Insulin resistance in young, lean male subjects with essencial hypertension. J Hum Hypertens, advance online publication 15 July 2010.
10. Yang T, Sun M, Zhou H, Xie X. Alteration of blood glucose, insulin and lipid in the offsprings of patients with essential hypertension. Hunan Yi Ke Da Xue Xue Bao 1999;24:37-40.
11. Anan F, Masaki T, Ono E e cols. Predictors for prehypertension in patients with impared glucose tolerance. Hypertens Res 2008;31:1913-1920.
12. Fuenmayor N, Moreira E, Cubeddu LX. Sal sensitivity is associated with insulin resistance in essencial hypertension. Am J Hypertens 1998;11:397-402.
13. Lima NKC, Tozetto DGO, Lima LG e cols. Salt and insulin sensitivity after short and prolonged high salt intake in elderly subjects. Bras J Med Biol Res 2009;42:738-743.
14. Hosaka M, Mimura A, Asayama K e cols. Relationship of dysregulation of glucose metabolism with white-coat hypertension: the Ohasama study. Hypertens Res 2010;33:937:943.
15. Kidambi S, Kotchen JM, Krishnaswami S. Cardiovascular correlates of insulin resistance in normotensive and hypertensive African Americans. Metabolism, advance online publication 2010.
16. Nakamura K, Sakurai M, Miura K e cols. Homeostasis model assessment of insulin resistance and the risk of cardiovascular events in middle-aged non-diabetic Japanese men. Diabetologia 2010;53:1894-1902.
17. Nilsson P, Nilsson J-A, Hedblad B, Eriksson K-F, Berglund G. Hyperinsulinemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmo Preventive Study. J Int Med 2003;253:136-145.
18. Trovato GM, Pirri C, Martines GF, Tonzuso A, Trovato F, Catalano D. Lifestyle interventions, insulinresistance, and renal artery stiffness in essencial hypertension. Clin Exp Hypertens 2010;32:262-269.
19. Masajtis-Zagajewska A, Majer J, Nowicki M. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients - a randomized, crossover trial. Hypertens res 2010;33:348-353.
20. Schneider F, Vossler S, Franke S, Bar F, Konrad T. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. Int J Clin Pharmacol Ther 2009;47:311-20.
21. Leonhardt W, Pfutzner A, Muller J e cols. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Atherosclerosis 2008;201:155-162.
22. Abbasi F, NK Lima, Reaven GM. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism 2009;58:373-378.
23. Luque-Ramirez M, Escobar-Morreale HF. Treatment of Polycystic Ovary Syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with decrease of serum interleukin-6 concentrations. Horm Metab Res 2010;42:815-820.
24. Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci 2010;1205:192-198.